Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Leuprolide

Lupron · GnRH Long-Acting Agonist

Evidence grade 5 of 5, Settled. Read how the Atlas grades evidence.

Leuprolide acetate is an FDA-approved GnRH agonist backed by decades of randomized and depot-formulation trials across its labeled indications: advanced prostate cancer (androgen-deprivation therapy), endometriosis pain, preoperative uterine fibroids, and central precocious puberty, plus adjunctive use in assisted reproduction. Evidence for these approved uses is overwhelming and consensus-level, so grade 5 is retained. The high grade applies only to the approved medical indications; the drug is a hormone-suppression agent and carries documented long-term harms.

FDA
FDA Approved (Lupron)
WADA
Prohibited in males (S2)

Reference only. Not medical advice.

What can go wrong

Sustained hypogonadism; bone-density loss and a cardiovascular signal with long-term androgen-deprivation use; not for wellness optimization.

Talk to a clinician before taking this, particularly if you have any history of cancer. The Atlas can tell you what has been studied about Leuprolide. It cannot tell you how it would interact with your body, your history, or anything else you are taking, and nothing on this page is a reason to start.

A long-acting GnRH agonist, FDA-approved for prostate cancer, endometriosis, and precocious puberty. Paradoxically suppresses sex hormones through pituitary desensitization.

What people take it for

What it is taken for. Approval, where it exists, covers only some of these.

  • Prostate cancer
  • Endometriosis
  • Precocious puberty
Advanced prostate cancer (Lupron)
FDA-approved in 1989 to suppress testosterone to castrate levels in advanced prostate cancer, a first-line hormone therapy that, with its class, largely replaced surgical castration.
Endometriosis and uterine fibroids
Approved to lower estrogen for endometriosis and to shrink fibroids and reduce bleeding before surgery, used short-term, often with add-back therapy to limit bone loss.
Central precocious puberty
Approved to slow premature puberty in children, preserving predicted adult height, a genuine pediatric use under specialist care.

How it works

Leuprolide is a GnRH agonist, and like others in its class it works through a paradox. Given continuously, it first stimulates the pituitary, a brief surge of LH, FSH, testosterone and estrogen called the flare, then desensitizes the receptors so the pituitary stops responding, dropping sex hormones to castrate levels. By switching off testosterone in men and estrogen in women, it starves hormone-driven conditions like prostate cancer, endometriosis and fibroids of the hormones that feed them.

Leuprolide is a synthetic nonapeptide, nine amino acids, an analog of GnRH and a superagonist far more potent than the natural hormone, carrying a D-leucine and an ethylamide modification. Sold as Lupron, Eligard and Camcevi, it is given as daily injections or, far more commonly, long-acting depot injections lasting one to six months.

Type
GnRH agonist nonapeptide
Action
Flare, then suppression
Result
Castrate-level hormones
Form
Daily or depot
Approved
1989
WADA
Relevant (males)

The Agonist That Replaced Surgical Castration

Leuprolide, best known as Lupron, is the GnRH agonist most people have heard of, and one of the most widely prescribed hormone-suppressing medicines in the US. Approved in 1989, it is the drug that, with its class, largely replaced surgical castration in managing prostate cancer, achieving the same testosterone suppression with an injection instead of surgery. Its mechanism is the same agonist paradox seen with triptorelin, an initial flare followed by deep suppression, and its approved uses span prostate cancer, endometriosis, uterine fibroids and central precocious puberty in children. It is a genuinely important, evidence-backed medicine. The honest footnotes are commercial rather than scientific: its long-acting depot has been expensive with limited generic competition, and its maker has a history of marketing controversy, reminders that even essential approved drugs sit inside commercial systems.

Safety in detail

For approved medical indications only. Long-term GnRH-agonist hormone suppression is associated with bone mineral density loss and, in prostate-cancer androgen-deprivation therapy, a cardiovascular event signal relative to GnRH antagonists. In pediatric central precocious puberty the FDA added a pseudotumor cerebri warning to labeling on July 1, 2022, and labeling documents psychiatric events including emotional lability, depression, and rare suicidal ideation and attempt. Pediatric outcome studies associate treatment with preserved or improved adult height and an acceptable safety profile, but long-term late effects remain an area of active monitoring.

  • It produces the effects of a low-sex-hormone state: hot flashes, bone density loss, mood changes and reduced libido.
  • The initial flare can transiently worsen prostate-cancer symptoms, so it is often covered with an antiandrogen at the start.
  • Bone loss limits the duration of endometriosis courses, often managed with add-back therapy.
  • The pediatric precocious-puberty use is specialist-managed and has drawn long-term-side-effect discussion.
  • It is contraindicated in pregnancy and is relevant to anti-doping in males.

Children and teenagers

Leuprolide has a genuine, important pediatric use: slowing central precocious puberty to preserve predicted adult height, under pediatric endocrinology, and it is also used as a puberty blocker in gender-affirming care for adolescents under specialist care. These are legitimate, supervised medical uses, though the precocious-puberty use has prompted long-term-side-effect discussion. Any pediatric use belongs strictly with specialists.

What people get wrong

Nothing recorded here yet. There is almost certainly something people get wrong about this one, and the blank space means we have not written it down, not that the record is clean.

Who profits, and who pushes back

Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.

Leuprolide’s economy is dominated by its long-acting depot, a blockbuster with limited generic competition that has made it one of the most prescribed and lucrative hormone therapies, alongside generic daily forms and other brands. The honest backdrop includes its depot pricing and a notable marketing-fraud case in the drug’s commercial history, a reminder that an essential medicine can also be a major commercial product worth scrutinizing.

How we got here

Leuprolide is a synthetic nonapeptide GnRH (LHRH) agonist first marketed as Lupron by TAP Pharmaceuticals and later AbbVie. It is delivered through many depot and sustained-release formulations, including Lupron Depot, Eligard, Fensolvi, and Camcevi, and is used to treat advanced prostate cancer, endometriosis, and central precocious puberty. Leuprorelin is the international nonproprietary name for the same molecule.

After GnRH was discovered in 1971 and agonist analogs were developed in the 1980s, leuprolide was approved in 1989 and became the flagship of the class, known as Lupron. Long-acting depot formulations turned it into a blockbuster, and with its class it largely replaced surgical castration in prostate-cancer care. Generic daily forms followed while the depot retained limited competition, and its commercial history includes a notable marketing-fraud case alongside its central medical role.

  1. 1971GnRH is discovered.
  2. 1980sGnRH agonists are developed for medical use.
  3. 1989Leuprolide is approved and becomes the class flagship as Lupron.
  4. 1990s-2000sDepot formulations make it a blockbuster and replace surgical castration in practice.
  5. ongoingGeneric daily forms arrive while the depot retains limited competition.

The numbers behind the grade

Type
GnRH agonist
Brand
Lupron
Approved
1989
Use
Prostate cancer and more
Form
Depot
Role
Class flagship

The people taking it

The most widely known GnRH agonist, Lupron, one of the most-prescribed hormone-suppressing drugs in the US, first-line for prostate cancer and used across endometriosis, fibroids and precocious puberty.

Leuprolide’s users are predominantly men with prostate cancer, the main population, along with women with endometriosis or fibroids, children with precocious puberty under specialists, and patients in fertility and gender-affirming care. It serves large oncology and reproductive-medicine populations.

Approved for prostate cancer, endometriosis, uterine fibroids and central precocious puberty, with off-label fertility and gender-affirming uses. The dominant, most-prescribed GnRH agonist.

Set against the alternatives

Against triptorelin, leuprolide is the same class and mechanism, both continuous GnRH agonists that suppress the axis, but leuprolide is the dominant, earliest-approved and most-prescribed of them, the one known as Lupron. Against gonadorelin, it is the same receptor used the opposite way, continuous suppression versus pulsed stimulation, which completes the GnRH trio in this library. And against the newer GnRH antagonists like degarelix, which suppress without the initial flare, leuprolide’s flare is a relative drawback in prostate cancer. Its strength is a proven, first-line role and decades of use; its nuances are the flare and its cost.

What we do not know

  • How it compares with flare-free GnRH antagonists for prostate cancer.
  • What the long-term effects of the pediatric precocious-puberty use are.
  • How depot pricing and access will evolve with competition.
  • Its role across hormone-driven cancers and in gender-affirming care.

What could change

Antagonist competitionFlare-free GnRH antagonists challenge agonists in prostate cancer.Pediatric debateThe long-term effects of precocious-puberty use remain discussed.Depot pricingCompetition and biosimilar pressure may affect depot cost.Gender-affirming careIts puberty-suppression use is clinically important and publicly debated.

The market for this

What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.

Leuprolide is a prescription oncology and reproductive medicine, administered as a depot or daily injection under specialist care, the legitimate route. For its approved indications it is a first-line, well-established therapy, with depot cost a real consideration, and it is banned in sport for males.

The long-acting depot is expensive with limited generic competition, while generic daily leuprolide is cheaper. Cost and access are honest considerations, particularly for the depot.

Leuprolide comes from regulated pharmaceutical manufacturing, as branded depot and generic daily forms, with full quality assurance.

Branded depotThe long-acting depot is supplied through oncology and specialist channels with limited generic competition.Generic daily formGeneric leuprolide is available for the daily injection used in fertility protocols.Specialist administrationThe depot is administered in clinical settings under medical care.

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Leuprolide.

Nothing outstanding on this one.

Sources

The studies that matter

  • GnRH-agonist mechanismestablished

    Continuous leuprolide first stimulates then desensitizes the pituitary, suppressing LH, FSH and the sex hormones they drive.

  • Prostate cancer1980s-1990s

    Trials showed leuprolide suppresses testosterone to castrate levels as effectively as surgical castration, establishing it as first-line hormone therapy.

  • Endometriosis and fibroidsvarious

    Studies supported short-course use to lower estrogen in endometriosis and shrink fibroids before surgery.

  • Precocious pubertyvarious

    Established its use to slow premature puberty and preserve predicted adult height in children.

  • Depot development1990s-2000s

    Long-acting depot formulations extended dosing from daily to as long as six months.